[Effects of treatment with OKT3 on brain perfusion in a heart transplant patient with SPET with 99mTc-HMPAO].
A heart transplant patient treated with OKT3 developed a severe headache which worsened and was accompanied by a sudden decrease in the patient's consciousness level and aphasia when the treatment course was completed. CT was performed and was normal. SPET imaging with 99mTc-HMPAO of cerebral blood flow done 16 hours later revealed multiple and clear focal defects in the blood flow. Analysis of cerebral spinal fluid revealed aseptic pleocytosis. Five days after the completion of treatment, the symptoms remitted and a new control SPET 3 weeks later was completely normal. A diagnosis of neurotoxicity secondary to OKT3 administration was established.
Quirce
R
R
Servicio de Medicina Nuclear, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, 39008, España.
Carril
J
J
Vallina
N
N
Montero
A
A
Uriarte
I
I
D000328:Adult; D001037:Aphasia / Q000139:chemically induced / Q000000981:diagnostic imaging; D001922:Brain Abscess / Q000175:diagnosis; D001929:Brain Edema / Q000139:chemically induced / Q000000981:diagnostic imaging*; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D002543:Cerebral Hemorrhage / Q000175:diagnosis; D002555:Cerebrospinal Fluid / Q000166:cytology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003221:Confusion / Q000139:chemically induced / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D006261:Headache / Q000139:chemically induced / Q000000981:diagnostic imaging; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D007964:Leukocytosis / Q000139:chemically induced / Q000000981:diagnostic imaging; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008590:Meningoencephalitis / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000000981:diagnostic imaging*; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000494:pharmacology; D011183:Postoperative Complications / Q000139:chemically induced / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D019275:Radiopharmaceuticals; D019690:Technetium Tc 99m Exametazime